

## List of figures

Figures	Page No.
<b>Figure 1A.1.</b> $\alpha$ -amylose, a polymer of $\alpha$ -(1 $\rightarrow$ 4) linked D-glucose.	4
<b>Figure 1A.2.</b> Cellulose, a polymer of $\beta$ -(1 $\rightarrow$ 4) linked glucose.	4
<b>Figure 1A.3.</b> Pectin, a polymer of $\alpha$ -(1 $\rightarrow$ 4) galacturonic acid	5
<b>Figure 1A.4.</b> Structure of Chitin, $\beta$ -(1 $\rightarrow$ 4)-linked N-acetyl-D-glucosamine and Chitosan, $\beta$ -(1 $\rightarrow$ 4)-linked D-glucosamine.	5
<b>Figure 1A.5.</b> Heparin, a polymer of (1 $\rightarrow$ 4)-linked sulfated hexosamine and uronic acid.	6
<b>Figure 1A.6.</b> Guar gum, a polysaccharide of (1 $\rightarrow$ 4)-linked $\beta$ -D-manp units with side chains of (1 $\rightarrow$ 6)-linked $\alpha$ -D-galp	6
<b>Figure 1A.7.</b> Different parts of Mushroom	7
<b>Figure 1A.8.</b> Possible immune mechanism: $\beta$ -D-glucan as BRM to target cancer cells	12
<b>Figure 1B.1:</b> Top down and bottom up approach for the synthesis of metal nanoparticles	15
<b>Figure 1B.2.</b> Various approaches adopted in the synthesis of metal nanoparticles	16
<b>Figure 1B.3.</b> A schematic representation of polysaccharides mediated synthesis and stabilization of metal nanoparticles.	17
<b>Figure 1B.4.</b> Classification of Nanomaterials (a) 0D, (b) 1D, (c) 2D, (d) 3D	20
<b>Figure 2.1.</b> Schematic diagram of structural analysis of polysaccharides	24
<b>Figure 2.2.</b> Schematic diagram of isolation and purification of polysaccharides from alkaline extract of the fruit bodies, <i>Termitomyces heimii</i>	26
<b>Figure 2.3.</b> Schematic diagram of isolation and purification of polysaccharides from aqueous extract of <i>Lentinus fusipes</i> .	28
<b>Figure 2.4.</b> Schematic diagram of preparation of alditol acetates	30
<b>Figure 2.5.</b> Schematic diagram of preparation of PMAA of PS	31
<b>Figure 2.6.</b> Schematic diagram of periodate oxidation of (1 $\rightarrow$ 6)-	

---

linked hexopyranoside.	32
<b>Figure 2.7.</b> Schematic diagram of periodate oxidation study	33
<b>Figure 2.8.</b> Schematic diagram of NMR spectroscopic methods for the determination of structure of a polysaccharide.	3
	5
<b>Figure 3.1.</b> (a) Chromatogram of crude polysaccharide on Sepharose-6B column. (b) Chromatogram showing the homogeneous nature of PS-I isolated from mushroom <i>T. Heimii</i>	50
<b>Figure 3.2.</b> Determination of molecular weight of the PS-I isolated from <i>T. heimii</i>	50
<b>Figure 3.3.</b> Schematic presentation of methylation experiment of PS-I.	52
<b>Figure 3.4.</b> Schematic presentation of periodate oxidised reduced products of methylated PS-I.	53
<b>Figure 3.5.</b> $^1\text{H}$ NMR spectrum (500MHz, $\text{D}_2\text{O}$ , 30 °C) of PS-I isolated from the mushroom <i>T. heimii</i> .	54
<b>Figure 3.6.</b> $^{13}\text{C}$ NMR spectrum (125MHz, $\text{D}_2\text{O}$ , 30 °C) and part of DEPT-135 spectrum ( $\text{D}_2\text{O}$ , 30 °C) (inset) of PS-I.	55
<b>Figure 3.7.</b> Part of HSQC spectrum of PS-I isolated from the mushroom <i>T. heimii</i> .	55
<b>Figure 3.8.</b> Part of ROESY spectrum of PS-I isolated from the mushroom <i>T. heimii</i> .	57
<b>Figure 3.9.</b> $^{13}\text{C}$ NMR spectrum (125MHz, $\text{D}_2\text{O}$ , 30 °C) of Smith-degraded glycerol-containing disaccharide of PS-I isolated from the mushroom <i>T. heimii</i> .	59
<b>Figure 3.10.</b> MTT assay showing in-vitro cytotoxicity of PS-I on peripheral blood lymphocytes.	61
<b>Figure 3.11.</b> Concentration of reduced glutathione (GSH) level in normal human lymphocytes treated with different concentrations of PS-I.	62
<b>Figure 3.12.</b> Concentration of oxidized glutathione (GSSG) level in normal human lymphocytes treated with different concentrations of PS-I.	62
<b>Figure 3.13.</b> Concentration of MDA level of PS-I treated normal human lymphocytes to evaluate lipid peroxidation	63
<b>Figure 3.14.</b> MTT assay showing in-vitro cell viability of PS-I on	

---

nicotine stimulated peripheral blood lymphocytes.	63
<b>Figure 3.15.</b> Concentration of nitric oxide (NO) release in nicotine stimulated human lymphocytes treated with PS-I.	64
<b>Figure 3.16.</b> Fluorescence microscopic images (100X magnifications) showing intracellular ROS generation in lymphocytes. The scale bar represents 20µm (i) Control; (ii) Nicotine treated; (iii) Nicotine + 25 µg/ml of PS-I; (iv) Nicotine + 50µg/ml of PS-I. (v) Nicotine + 100 µg/ml of PS-I; (vi) Nicotine + 200 µg/ml of PS-I; (vii) Nicotine+400 µg/ml of PS-I; (viii) Histogram showing the mean fluorescent intensity.	65
<b>Figure 3.17.</b> Flow cytometry of human lymphocytes: (i) without any treatment (ii) Lymphocytes treated with 10 mM of Nicotine; and (iii) Lymphocytes treated with 10 mM of nicotine + 200µg/ml of PS-I.	66
<b>Figure 4.1.</b> Chromatogram of crude polysaccharide isolated from an edible mushroom <i>L. fusipes</i> using Sepharose 6B column.	70
<b>Figure 4.2.</b> Determination of molecular weight PS-II isolated from mushroom <i>L. Fusipes</i> .	70
<b>Figure 4.3:</b> GLC-MS analysis of alditol acetates of methylated PS-II.	71
<b>Figure 4.4.</b> Schematic presentation of methylation experiment of PS-II.	72
<b>Figure 4.5.</b> Schematic presentation of periodate oxidation reactions of PS-II.	73
<b>Figure 4.6.</b> FT-IR spectrum of PS-II isolated from an edible mushroom <i>L. fusipes</i> .	74
<b>Figure 4.7.</b> <sup>1</sup> H NMR spectrum (700MHz, D <sub>2</sub> O, 30 °C) of PS-II	75
<b>Figure 4.8.</b> <sup>13</sup> C NMR spectrum (175MHz, D <sub>2</sub> O, 30 °C) and part of DEPT-135 spectrum (D <sub>2</sub> O, 30 °C) (inset) of PS-II.	75
<b>Figure 4.9.</b> The HSQC spectrum of (a) anomeric part and (b) other than anomeric part of PS-II.	76
<b>Figure 4.10.</b> Part of ROESY spectrum of PS-II isolated from the mushroom <i>L. fusipes</i> .	78
<b>Figure 4.11.</b> Part of the HMBC spectrum of PS-II isolated from the mushroom <i>L. fusipes</i> .	80
<b>Figure 4.12.</b> <sup>13</sup> C NMR spectrum (125MHz, D <sub>2</sub> O, 30 °C) of Smith-	

---

---

degraded glycerol-containing material of PS-II.	82
<b>Figure 4.13.</b> MTT assay showing in-vitro cytotoxicity of PS-II on peripheral blood lymphocytes.	84
<b>Figure 4.14.</b> Concentration of reduced glutathione (GSH) level in normal human lymphocytes treated with different concentrations of PS-II.	84
<b>Figure 4.15.</b> Concentration of oxidized glutathione (GSSG) level in normal human lymphocytes treated with different concentrations of PS-II.	85
<b>Figure 4.16.</b> Concentration of MDA level of PS-II treated normal human lymphocytes to evaluate lipid peroxidation.	85
<b>Figure 4.17</b> (a) lymphocytes treated with 10 mM of Nicotine only and (b) lymphocytes treated with 10 mM of nicotine +160 µg/ml of PS-II.	86
<b>Figure 4.18.</b> Scavenging ability of PS-II on DPPH radicals.	87
<b>Figure 4.19.</b> <i>In vitro</i> macrophage activation using different concentrations of PS-II (in terms of NO production).	87
<b>Figure 4.20.</b> Effect of varied concentrations of PS-II on splenocyte proliferation.	88
<b>Figure 5.1:</b> Structure of hetero polysaccharide isolated from hot water extract of <i>Lentinus squarrosulus</i> (Mont.) Singer.	92
<b>Figure 5.2:</b> UV-vis spectra of AgNPs–PS with 0.05% (w/v) of PS at different time intervals. The peak at around 404 nm corresponds to the SPR of AgNPs.	93
<b>Figure 5.3:</b> UV-vis spectra of AgNPs–PS at different time intervals a) with 0.025% (w/v) of PS. The SPR peak at around 423 nm b) with 0.025% (w/v) of PS. The SPR peak at around 449 nm.	93
<b>Figure 5.4:</b> (a) TEM images and the corresponding selected area electron diffraction (SAED) patterns (inset) of AgNPs-PS. (b) Particle size distribution histogram. (c) XRD patterns of freeze dried AgNPs- glucan conjugates, all the peaks could be indexed to fcc lattice of silver.	94
<b>Figure 5.5:</b> Effect of varying concentration of Ag NPs–PS conjugates on the growth of <i>Escherichia coli</i> strain MREC33 in MH broth.	95

**Figure 5.6.** DNA degradation using FACS analysis of *E. coli* MREC33 cells (A) DAPI treated control cells; (B) cells treated with DAPI and 40 µg/mL AgNPs–PS conjugates. Side scattering analysis of: (C) DAPI treated control cell; and (D) AgNP–PS and DAPI treated MREC33 cell using FACS. **97**

**Figure 5.7.** Hemolysis study of human RBCs treated with LD<sub>50</sub> concentration of AgNPs–PS conjugates. RBCs suspended in water used as positive control and in PBS as negative control. **98**

**Figure 5.8.** Synergistic antibacterial effects of the Ag NPs–PS conjugate at 5 µg/ml in combination with (a) ampicillin, (b) azithromycin, (c) kanamycinand (d) netilmicin. **98**